Corindus Vascular Robotics Inc (NYSEMKT:CVRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

Separately, B. Riley started coverage on Corindus Vascular Robotics in a research note on Tuesday, October 11th. They issued a “buy” rating and a $3.00 target price for the company.

Corindus Vascular Robotics (NYSEMKT:CVRS) opened at 0.78 on Monday. Corindus Vascular Robotics has a 1-year low of $0.73 and a 1-year high of $3.50. The firm’s market cap is $92.84 million. The stock has a 50 day moving average price of $0.91 and a 200 day moving average price of $1.20.

Corindus Vascular Robotics (NYSEMKT:CVRS) last announced its quarterly earnings data on Tuesday, November 8th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.01. On average, analysts anticipate that Corindus Vascular Robotics will post ($0.26) EPS for the current year.

Several hedge funds have recently modified their holdings of CVRS. Schwab Charles Investment Management Inc. increased its stake in shares of Corindus Vascular Robotics by 236.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 84,000 shares of the company’s stock worth $121,000 after buying an additional 59,000 shares during the period. California State Teachers Retirement System boosted its position in shares of Corindus Vascular Robotics by 139.3% in the second quarter. California State Teachers Retirement System now owns 115,258 shares of the company’s stock worth $165,000 after buying an additional 67,091 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Corindus Vascular Robotics by 44.4% in the second quarter. Bank of New York Mellon Corp now owns 164,570 shares of the company’s stock worth $235,000 after buying an additional 50,636 shares in the last quarter. BlackRock Investment Management LLC boosted its position in shares of Corindus Vascular Robotics by 128.5% in the second quarter. BlackRock Investment Management LLC now owns 178,093 shares of the company’s stock worth $255,000 after buying an additional 100,170 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Corindus Vascular Robotics by 12.3% in the second quarter. State Street Corp now owns 258,877 shares of the company’s stock worth $369,000 after buying an additional 28,377 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Corindus Vascular Robotics Inc (CVRS) Stock Rating Upgraded by Zacks Investment Research” was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2016/11/23/corindus-vascular-robotics-inc-cvrs-stock-rating-upgraded-by-zacks-investment-research.html.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures (the CorPath System). The Company operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The Company’s product, the CorPath 200 System, is a vascular robotic system, which is engaged in stent placement in percutaneous coronary intervention (PCI) procedures.

Receive News & Stock Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related stocks with our FREE daily email newsletter.